Takeda entered into a collaboration with Evotec designed to establish at least five drug discovery programmes across multiple therapeutic areas, the German company announced Tuesday. Under the deal, Evotec will validate therapeutic hypotheses and advance small-molecule programmes, with Takeda having options to assume responsibility following delivery of preclinical candidates.
According to Evotec, Takeda will make an undisclosed upfront payment to access the German drugmaker's platforms. Evotec added that it is also eligible to receive milestones of more than $170 million per programme, as well as tiered royalties on future sales.
Evotec said that the collaboration will combine its experience in fully integrated drug discovery programmes with Takeda's strategic insights in its four core therapeutic areas of oncology, gastroenterology, neuroscience and rare diseases. Steve Hitchcock, global head of research at Takeda, noted that the Japanese drugmaker "has a long history of working with Evotec and is confident in [its] capabilities."
In 2011, Takeda and Evotec entered into a collaboration to identify small-molecule modulators against GPCR and protease targets involved in various central nervous system and metabolic diseases.
To read more Top Story articles, click here.